Elevation Oncology, Inc. (ELEV) has disclosed a new risk, in the Debt & Financing category.
Elevation Oncology, Inc. faces significant business risk due to its reliance on securing additional capital to continue its operations. There is substantial doubt about the company’s ability to persist as a going concern, as it needs financing to advance the development and commercialization of its product candidates EO-3021 and EO-1022. The current challenging financial environment, coupled with macroeconomic and geopolitical uncertainties, complicates their ability to raise funds on favorable terms. Without securing necessary financing, Elevation Oncology may be forced to curtail or cease its product development efforts, impacting its long-term viability.
The average ELEV stock price target is $7.67, implying 1,401.57% upside potential.
To learn more about Elevation Oncology, Inc.’s risk factors, click here.